Trials / Completed
CompletedNCT01230645
RV568 - Viral Challenge With RSV
A Randomized, Single-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Intranasal RV568 (400μg) Administered Twice Daily to Adult Male Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Respivert Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568 is effective in reducing the inflammation caused by viral infections such as RSV (respiratory syncytial virus).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RV568 | RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8) |
| DRUG | Placebo | Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8) |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2010-12-01
- Completion
- 2011-01-01
- First posted
- 2010-10-29
- Last updated
- 2011-02-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01230645. Inclusion in this directory is not an endorsement.